Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathogenesis, lethality, and immunizing effect of experimental cutaneous cryptococcosis.

M A Dykstra, L Friedman

    Infection and Immunity
    |May 1, 1978
    PubMed
    Summary

    A cutaneous Cryptococcus neoformans infection in mice shows limited local yeast multiplication and delayed systemic spread. Vaccination with a live lesion offers partial protection against subsequent subcutaneous challenge, but not intravenous challenge.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Description and predictors of self-determination in males and females with fragile X syndrome on the verge of adulthood.

    Journal of intellectual disability research : JIDR·2024
    Same author

    Characterising the social interaction style of autism in young adult males with fragile X syndrome.

    Journal of intellectual disability research : JIDR·2024
    Same author

    Human rabies postexposure prophylaxis and rabid terrestrial animals in Ontario, Canada: 2014-2016.

    Canada communicable disease report = Releve des maladies transmissibles au Canada·2019
    Same author

    Influenza outbreaks in Ontario hospitals, 2012-2016.

    Canada communicable disease report = Releve des maladies transmissibles au Canada·2019
    Same author

    Sex ratio in dementia with Lewy bodies balanced between Alzheimer's disease and Parkinson's disease dementia: a cross-sectional study.

    Alzheimer's research & therapy·2018
    Same author

    Postpartum hemoptysis as presenting sign of longstanding vasculitis.

    International journal of obstetric anesthesia·2018

    Area of Science:

    • Immunology
    • Mycology
    • Infectious Diseases

    Background:

    • Cryptococcus neoformans is a significant fungal pathogen causing cryptococcosis.
    • Understanding the host-pathogen interaction and immune response is crucial for developing effective treatments and vaccines.

    Purpose of the Study:

    • To investigate the course of a subcutaneous Cryptococcus neoformans infection in mice.
    • To evaluate the immunizing capacity of a cutaneous lesion against subsequent challenges.
    • To assess the role of antibodies and cryptococcal polysaccharide in the host response.

    Main Methods:

    • Mice were subcutaneously inoculated with virulent Cryptococcus neoformans.
    • Yeast viability was assessed weekly in excised tissue.
    • Antibody (agglutinins) and cryptococcal polysaccharide levels were monitored.

    Related Experiment Videos

  • Vaccination efficacy was tested via subcutaneous and intravenous challenge with C. neoformans.

    • Main Results:

    • Yeast multiplied locally for at least 4 weeks, with reduced numbers by week 5.
    • Agglutinins were transient, while cryptococcal polysaccharide persisted.
    • Subcutaneous vaccination inhibited yeast multiplication at the challenge site and increased survival time after intravenous challenge.
    • Protection was dose-dependent and time-dependent, with killed cryptococci and adjuvant providing better protection against higher doses.

    Conclusions:

    • A cutaneous Cryptococcus neoformans infection establishes a localized, persistent infection with delayed systemic dissemination.
    • A live cutaneous lesion can induce partial protective immunity, particularly against local re-infection.
    • The study highlights the complexity of the immune response to C. neoformans and the potential for vaccine development.